MTHFD2 Inhibitors for treatment of AML
|Coordinator||Karolinska Institutet - Science for Life Laboratory|
|Funding from Vinnova||SEK 950 000|
|Project duration||June 2018 - May 2019|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
|Call||Förbättrad prevention, diagnos och behandling – Swelife och Medtech4health|
Purpose and goal
The project has reached the overarching objectives of progressing to TRL4 and nomination of a Candidate Drug for further preclinical development. Moreover, all milestones for advancing the project beyond Stop/Go decisions were successfully met, as well as the majority of deliverables defined for the Work Packages.
Expected results and effects
The project has advanced from Lead Optimization (TLR3) to Preclinical Development (TLR4) within a year, thus cost-effectively de-risking the therapeutic concept and thereby significantly increasing the commercial potential. Furthermore, the underlying molecular mechanism behind the cancer-specific phenotype induced by MTHFD2i has been unraveled.
Planned approach and implementation
The project has been able to reach the objectives by (a) from the outset defining productive work packages with realistic timelines and tangible deliverables; (b) effective collaborations between academia, clinicians and industry